| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 542.95M | 532.41M | 452.87M | 405.36M | 538.20M | 582.77M |
| Gross Profit | 542.95M | 530.62M | 451.10M | 403.71M | 536.21M | 578.69M |
| EBITDA | 71.61M | 46.81M | 295.00K | -77.65M | -105.18M | 66.27M |
| Net Income | 50.34M | 10.06M | -28.21M | -88.72M | -104.38M | 45.45M |
Balance Sheet | ||||||
| Total Assets | 1.05B | 1.16B | 1.11B | 1.11B | 1.15B | 1.04B |
| Cash, Cash Equivalents and Short-Term Investments | 75.30M | 82.24M | 121.65M | 144.40M | 123.23M | 93.38M |
| Total Debt | 92.73M | 96.92M | 103.16M | 106.80M | 41.37M | 46.56M |
| Total Liabilities | 162.95M | 567.00M | 209.26M | 461.66M | 399.77M | 202.46M |
| Stockholders Equity | 884.47M | 588.43M | 904.08M | 650.96M | 749.52M | 837.56M |
Cash Flow | ||||||
| Free Cash Flow | -29.85M | -31.22M | -17.47M | -42.38M | -183.48M | -131.62M |
| Operating Cash Flow | -17.06M | -18.37M | -6.69M | -26.87M | -162.62M | -107.86M |
| Investing Cash Flow | 27.04M | -48.42M | -15.89M | 25.86M | -12.63M | -73.28M |
| Financing Cash Flow | -10.80M | -9.67M | -6.22M | 63.84M | 213.24M | 201.25M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
58 Neutral | $123.06M | 102.70 | 5.88% | ― | 16.79% | ― | |
54 Neutral | $302.67M | -51.17 | 15.11% | ― | 13.16% | ― | |
46 Neutral | $21.94M | 8.86 | 4.56% | ― | 19.30% | -17.56% | |
44 Neutral | $38.62M | -0.15 | -142.05% | ― | 7.56% | -344.04% | |
44 Neutral | $5.09M | -0.22 | -146.43% | ― | -6.84% | 97.23% | |
43 Neutral | $11.96M | -0.10 | -11.18% | ― | 624.24% | 85.46% |
On January 6, 2026, eHealth announced that its subsidiary eHealthInsurance Services, Inc. entered into a new $125 million asset-based revolving credit facility with Manulife | Comvest Credit Partners, replacing its higher-cost term loan from Blue Torch Finance. The three-year facility, priced at SOFR plus 6.50%, features a flexible borrowing base with the potential to expand funding by up to $50 million, and part of the proceeds has already been used to fully repay roughly $70 million outstanding under the prior Blue Torch loan and related fees. The remaining capital is earmarked to support strategic growth initiatives, including investment in AI-driven capabilities, omni-channel technology and revenue diversification, while eHealth pursues further capital structure improvements, addresses its convertible Series A preferred stock, and enhances governance through a new Strategy Committee, underscoring a broader effort to strengthen its balance sheet and long-term competitive positioning. In connection with the facility, the company also amended its investment agreement with the holder of its convertible Series A preferred stock, signaling continued focus on aligning financing terms with its long-term value creation plans.
The most recent analyst rating on (EHTH) stock is a Hold with a $5.50 price target. To see the full list of analyst forecasts on Ehealth stock, see the EHTH Stock Forecast page.
On December 16, 2025, eHealth’s board adopted amended and restated bylaws, effective immediately, that adjust shareholder meeting notice deadlines to Eastern Time, refine rules for stockholder director nominations, define “principal competitor” for disclosure purposes, and clarify the company’s ability to maintain insurance for its directors, officers, employees, and agents, along with other technical and conforming updates. On December 18, 2025, the company reported that its latest Medicare Annual Enrollment Period delivered enrollments and revenue in line with expectations but stronger-than-anticipated profitability, supported by a shift toward higher-quality direct branded channels and the deployment of AI screeners to improve marketing yield and sales efficiency, and it raised full-year 2025 guidance for total revenue, GAAP net income, and adjusted EBITDA, while modestly trimming the upper end of its operating cash flow outlook, signaling improved earnings power and tighter operational discipline for investors and other stakeholders.
The most recent analyst rating on (EHTH) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Ehealth stock, see the EHTH Stock Forecast page.